^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Acute Lymphocytic Leukemia
    Drug:Marqibo (vincristine liposomal) (Tubulin polymerization inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    Marqibo® is indicated for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Acute Lymphoblastic Leukemia: Other Recommended regimens…Vincristine sulfate liposome injection (VSLI)